Format

Send to

Choose Destination
Acta Oncol. 2016 Dec;55(12):1400-1407. Epub 2016 Jun 22.

Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study.

Author information

1
a Center for Cancer Treatment, Sørlandet Hospital , Kristiansand , Norway.
2
b Department of Obstetrics and Gynecology, Sørlandet Hospital , Kristiansand , Norway.
3
c Department of Oncology , Innlandet Hospital , Gjøvik , Norway.
4
d Department of Oncology, Oslo University Hospital , Oslo , Norway.
5
e Department of Oncology , Stavanger University Hospital , Stavanger , Norway.
6
f Department of Public Health and General Practice , Norwegian University of Science and Technology, Trondheim and the Norwegian Institute of Public Health , Oslo , Norway.
7
g K. G. Jebsen Colorectal Cancer Research Centre , Oslo University Hospital , Oslo , Norway.

Abstract

BACKGROUND AND PURPOSE:

Palliative pelvic radiotherapy (PPRT) is used to treat locally advanced rectal cancer (RC) although symptomatic effects and toxicities are poorly documented. Aims were to evaluate symptom severity, quality of life (QOL) and toxicity after PPRT.

MATERIAL AND METHODS:

Fifty-one patients with symptomatic primary or recurrent RC prescribed PPRT with fractions of 3 Gy to 30-39 Gy were included. Primary outcome was severity of target symptoms (TS) 12 weeks after PPRT. Pelvic symptom burden, toxicity, and QOL were assessed. Response was defined as patient-reported TS improvement or resolution.

RESULTS:

Pain (n = 24), rectal dysfunction (n = 16), and hematochezia (n = 9) were the most common TSs. Overall response rate among evaluable patients 12 weeks after PPRT was 28/33 (85%). Eighteen patients did not complete the study follow-up, 16 due to deteriorating health. TS responses were 10/13 (77%) for pain, 9/10 (90%) for rectal dysfunction, and 8/8 for hematochezia. Non-target pelvic symptom severity decreased and median QOL scores remained stable. There was no grade 4 toxicity. Median survival was nine months.

CONCLUSIONS:

In the majority of patients with symptomatic primary or recurrent RC, PPRT with 30-39 Gy contributes to pelvic symptom relief, with little toxicity. Patients prescribed PPRT of RC have limited life expectancy. Future studies should investigate simplification of PPRT.

PMID:
27332723
DOI:
10.1080/0284186X.2016.1191666
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for Norwegian BIBSYS system
Loading ...
Support Center